[{"address1": "7707 Gateway Boulevard", "address2": "Suite 140", "city": "Newark", "state": "CA", "zip": "94560", "country": "United States", "phone": "510 474 0170", "website": "https://www.protagonist-inc.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide, an injectable mimetic of hepcidin that is in phase 3 clinical trials for the treatment of polycythemia vera; Icotrokinra, an orally delivered investigational drug which is in phase 3 clinical trials indicated to block biological pathways targeted by marketed injectable antibody drugs; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company also develops IL-17 oral peptide antagonist PN-88,1 an oral metabolic/obesity peptide program, and an oral hepcidin mimetic/ferroportin blocker that is in pre-clinical stage. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.", "fullTimeEmployees": 126, "companyOfficers": [{"maxAge": 1, "name": "Dr. Dinesh V. Patel Ph.D.", "age": 67, "title": "CEO, President, Secretary & Director", "yearBorn": 1957, "fiscalYear": 2023, "totalPay": 1026472, "exercisedValue": 0, "unexercisedValue": 10583697}, {"maxAge": 1, "name": "Mr. Matthew M. Gosling J.D.", "age": 53, "title": "Executive VP & General Counsel", "yearBorn": 1971, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Carena  Spivey", "title": "Head of HR & Senior VP of Human Resources", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Ashok  Bhandari Ph.D.", "age": 60, "title": "Executive VP & Chief Drug Discovery and Preclinical Development Officer", "yearBorn": 1964, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Carter J. King", "age": 53, "title": "Executive Vice President of Business Development", "yearBorn": 1971, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Arturo M. Molina FACP, M.D., M.S.", "age": 65, "title": "Chief Medical Officer", "yearBorn": 1959, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Samuel R. Saks M.D.", "age": 69, "title": "Clinical Development Advisor", "yearBorn": 1955, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 7, "compensationRisk": 9, "shareHolderRightsRisk": 7, "overallRisk": 8, "governanceEpochDate": 1743465600, "compensationAsOfEpochDate": 1703980800, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 40.89, "open": 41.1, "dayLow": 41.1, "dayHigh": 42.63, "regularMarketPreviousClose": 40.89, "regularMarketOpen": 41.1, "regularMarketDayLow": 41.1, "regularMarketDayHigh": 42.63, "payoutRatio": 0.0, "beta": 2.295, "trailingPE": 10.07565, "forwardPE": -29.804195, "volume": 1156290, "regularMarketVolume": 1156290, "averageVolume": 1093495, "averageVolume10days": 1509090, "averageDailyVolume10Day": 1509090, "bid": 42.46, "ask": 42.73, "bidSize": 2, "askSize": 3, "marketCap": 2616198912, "fiftyTwoWeekLow": 24.22, "fiftyTwoWeekHigh": 60.6, "priceToSalesTrailing12Months": 6.0221, "fiftyDayAverage": 43.852, "twoHundredDayAverage": 41.92785, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 2319870720, "profitMargins": 0.63344, "floatShares": 49266417, "sharesOutstanding": 61384300, "sharesShort": 5129814, "sharesShortPriorMonth": 4221220, "sharesShortPreviousMonthDate": 1739491200, "dateShortInterest": 1741910400, "sharesPercentSharesOut": 0.0836, "heldPercentInsiders": 0.01381, "heldPercentInstitutions": 1.05287, "shortRatio": 3.53, "shortPercentOfFloat": 0.0847, "impliedSharesOutstanding": 61384300, "bookValue": 11.064, "priceToBook": 3.8521328, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "earningsQuarterlyGrowth": 3.817, "netIncomeToCommon": 275188000, "trailingEps": 4.23, "forwardEps": -1.43, "enterpriseToRevenue": 5.34, "enterpriseToEbitda": 9.145, "52WeekChange": 0.60346127, "SandP52WeekChange": 0.059571505, "quoteType": "EQUITY", "currentPrice": 42.62, "targetHighPrice": 82.0, "targetLowPrice": 45.0, "targetMeanPrice": 69.1, "targetMedianPrice": 69.0, "recommendationMean": 1.6, "recommendationKey": "buy", "numberOfAnalystOpinions": 10, "totalCash": 418912992, "totalCashPerShare": 6.824, "ebitda": 253668992, "totalDebt": 10866000, "quickRatio": 12.393, "currentRatio": 12.482, "totalRevenue": 434432992, "debtToEquity": 1.609, "revenuePerShare": 7.056, "returnOnAssets": 0.28662002, "returnOnEquity": 0.54386, "grossProfits": 434432992, "freeCashflow": 65107876, "operatingCashflow": 184152000, "earningsGrowth": 3.513, "revenueGrowth": 1.844, "grossMargins": 1.0, "ebitdaMargins": 0.58391, "operatingMargins": 0.74297994, "financialCurrency": "USD", "symbol": "PTGX", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "corporateActions": [], "postMarketTime": 1744411058, "regularMarketTime": 1744401600, "exchange": "NGM", "messageBoardId": "finmb_129263324", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": 4.230862, "regularMarketPrice": 42.62, "marketState": "CLOSED", "postMarketChangePercent": 1.36087, "postMarketPrice": 43.2, "postMarketChange": 0.580002, "regularMarketChange": 1.7299995, "regularMarketDayRange": "41.1 - 42.63", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 1093495, "fiftyTwoWeekLowChange": 18.4, "fiftyTwoWeekLowChangePercent": 0.75970274, "fiftyTwoWeekRange": "24.22 - 60.6", "fiftyTwoWeekHighChange": -17.98, "fiftyTwoWeekHighChangePercent": -0.29669967, "fiftyTwoWeekChangePercent": 60.346127, "earningsTimestamp": 1740144600, "earningsTimestampStart": 1746475200, "earningsTimestampEnd": 1746820800, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": 4.23, "epsForward": -1.43, "epsCurrentYear": -1.22625, "priceEpsCurrentYear": -34.75637, "fiftyDayAverageChange": -1.2320023, "fiftyDayAverageChangePercent": -0.02809455, "twoHundredDayAverageChange": 0.6921501, "twoHundredDayAverageChangePercent": 0.016508123, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.6 - Buy", "cryptoTradeable": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1470922200000, "shortName": "Protagonist Therapeutics, Inc.", "longName": "Protagonist Therapeutics, Inc.", "displayName": "Protagonist Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-04-12"}]